No Effect on Liver Markers from CPAP Type for Sleep Apnea Patients
Patients suffering from non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnea (OSA) may turn to different ways to mark liver fat quantities, MD Magazine reports.
A team, led by David Hui, BBS, Medicine & Therapeutics, Chinese University of Hong Kong, examined whether intrahepatic triglyceride content measured by proton-magnetic resonance spectroscopy (MRS) could be the new gold standard for liver fat quantification.
While obstructive sleep apnea is linked to the development of NAFLD, proton-magnetic resonance spectroscopy estimating proton density fat fraction is a novel biomarker that is more sensitive than liver biopsies to determine steatosis grade in assessing changes in the liver fat content.
from Sleep Review https://www.sleepreviewmag.com/sleep-health/sleep-whole-body/no-effect-on-liver-markers-from-cpap-type-for-sleep-apnea-patients/